Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis

Qian Zhang1, Ming Li2, Li You1, Haiming Li1, Li Ni1, Yong Gu1, Chuanming Hao1,2, Jing Chen1*

1 Division of Nephrology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China, 2 Department of Respiratory Medicine, Shanghai Tenth People’s Hospital Affiliated to Tongji University, Shanghai, China, 3 Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

Abstract

Purpose: Secondary hyperparathyroidism (SHPT) is one of the most common abnormalities of mineral metabolism in patients with chronic kidney disease. We performed a meta-analysis to determine the effect and safety of cinacalcet in SHPT patients receiving dialysis.

Methods: The meta-analysis was performed to determine the effect and safety of cinacalcet in SHPT patients receiving dialysis by using the search terms ‘cinacalcet’ or ‘mimpara’ or ‘sensipar’ or ‘calcimimetic’ or ‘R586’ on MEDLINE and EMBASE (January 1990 to February 2012).

Results: Fifteen trials were included, all of which were performed between 2000 and 2011 enrolling a total of 3387 dialysis patients. Our study showed that calcimimetic agents effectively ameliorated iPTH levels (WMD, −294.36 pg/mL; 95% CI, −322.76 to −265.95, P < 0.001) in SHPT patients and reduced serum calcium (WMD, −0.81 mg/dL; 95% CI, −0.89 to −0.72, P < 0.001) and phosphorus disturbances (WMD, −0.29 mg/dL; 95% CI, −0.41 to −0.17, P < 0.001). The percentage of patients in whom there was a 30% decrease in serum iPTH levels by the end of the dosing was higher in cinacalcet group than that in control group (OR = 10.75, 95% CI: 6.65–17.37, P < 0.001). However, no significant difference was found in all-cause mortality and all adverse events between calcimimetics and control groups (OR = 0.86, 95% CI: 0.46–1.60, P = 0.630; OR = 1.30, 95% CI: 0.78–2.18, P = 0.320, respectively). Compared with the control therapy, there was a significant increase in the episodes of hypocalcemia (OR = 2.46, 95% CI: 1.58–3.82, P < 0.001), nausea (OR = 2.45, 95% CI: 1.29–4.66, P = 0.006), vomiting (OR = 2.78, 95% CI: 2.14–3.62, P < 0.001), diarrhea (OR = 1.51, 95% CI: 1.04–2.20, P = 0.030) and upper respiratory tract infection (OR = 1.79, 95% CI: 1.20–2.66, P = 0.004) in calcimimetics group.

Conclusions: Calcimimetic treatment effectively improved biochemical parameters of SHPT patients receiving dialysis without increasing all-cause mortality and all adverse events.

Introduction

Secondary hyperparathyroidism (SHPT) is one of the most common abnormalities of mineral metabolism in patients with chronic kidney disease (CKD), and is characterized by hyperplasia of the parathyroid glands and increased plasma levels of parathyroid hormone (PTH) [1]. It is well documented that disturbance in vitamin D, phosphorus, calcium and PTH metabolism contributes to bone disorders and cardiovascular complications of end stage renal disease patients and is associated with the morbidity and mortality of this population [2,3].

The traditional treatment for SHPT is oral or intravenous administration of vitamin D sterols to lower PTH levels and (Ca-and non-Ca based) phosphate binders to control hyperphosphatemia. Although vitamin D sterols have been shown to be effective in suppressing elevation of serum PTH levels, they also increase serum P and Ca levels through stimulating gastrointestinal absorption [4], and therefore only a few patients were able to achieve the recommended therapeutic targets [5].

The calcium-sensing receptor (CaR) is a G protein–coupled cell-surface receptor that binds calcium ions and senses extracellular levels of calcium ion [6,7]. The calcimimetic agents increase the sensitivity of CaR to extracellular Ca ion levels, leading to decreased PTH synthesis and secretion [8]. In 2004, the US Food and Drug Administration (FDA) approved cinacalcet (Sensipar) as the first calcimimetic drug for the treatment of SHPT. It improves

Citation: Zhang Q, Li M, You L, Li H, Ni L, et al. (2012) Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis. PLoS ONE 7(10): e48070. doi:10.1371/journal.pone.0048070

Editor: Emmanuel A. Burdmann, University of Sao Paulo Medical School, Brazil

Received April 21, 2012; Accepted September 20, 2012; Published October 25, 2012

Copyright: © 2012 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by China Natural Science Foundation 30971373 and 81170684 (to Jing Chen) and New Century Grant for the Talented People by National Education Committee of China (to Jing Chen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

E-mail: chenjing_1998@yahoo.com.cn

* These authors contributed equally to this work.
PTH control without increasing circulating levels of calcium and phosphate [9]. The benefits and the adverse effects of calcimimetics vs. conventional therapy in dialysis patients with SHPT remain uncertain. The primary goal of this meta-analysis was to determine the effects and safety of cinacalcet in dialysis patients with SHPT.

Patients and Methods

Data Sources

A literature search was performed using the relevant search terms ‘cinacalcet’ or ‘nimpara’ or ‘sensipar’ or ‘calcimimetic’ or ‘R586’ on MEDLINE (January 1990 to February 2012) and EMBASE (January 1990 to February 2012) (Figure 1). These terms were also searched in the abstracts of conference proceedings of the American Society of Nephrology (ASN) between 1996 and 2011. Only randomized controlled trials that fulfilled the criteria of a highly sensitive filter were included in this study [10]. References of all included trials and review articles were scanned for additional studies.

Study Selection

Study reports were included if they: (1) were randomized controlled trials; (2) enrolled adult human subjects undergoing dialysis and receiving calcimimetic agents or control treatment (placebo, conventional care); and (3) were clinical trials regardless of the publication status (published, conference proceedings, or unpublished), trial year, and language of publication. Two individuals independently inspected each reference and applied the inclusion criteria. For possibly relevant articles or in cases of disagreement, all authors would inspect the full article independently.

Data Extraction and Quality Assessment

Two individuals independently extracted data from all primary studies that fulfilled the inclusion criteria, with disagreements resolved by consensus. For studies without reporting the outcome, the authors would be contacted for additional information. The same reviewers independently assessed trials for methodological quality using the Jadad scoring system [11], with disagreements resolved by consensus. The Jadad score is based on the explicit description of the study in the text as ‘randomized’ and ‘double-blind’, and reporting of “withdrawals and dropouts”.

Definition of Outcomes

The following biochemical outcomes were considered: values for intact PTH (iPTH), serum calcium level, serum phosphorus and calcium-phosphorus product levels, bone alkaline phosphatase, osteocalcin and tartrate-resistant acid phosphatase. Patient-level outcomes included: all-cause mortality, all adverse events, hypocalcemia, nausea, vomiting, diarrhoea, dyspnea, upper respiratory tract infection, and headache.

Data Synthesis and Analysis

Data were analyzed using Review Manager (RevMan, Version 5.0, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). Means and SDs were obtained for all continuous variables. When they were not available, they would be calculated from data obtained from the investigators, from figures, or by recalculating from other effect estimates and dispersion measures [10]. Mean differences (MDs) were analyzed for continuous variables. Dichotomous data were compared using an odds ratio (OR). Respective 95% CI was calculated for each estimate and presented in forest plots. The statistical heterogeneity of trial results was assessed using the χ2 test for heterogeneity and the I2 test for inconsistency [12,13]. If the P value was less than 0.1 (χ2 test), the results were considered heterogeneous; if the I2 was greater than 50%, the results were considered inconsistent [14]. If the test results for heterogeneity were significant, the DerSimonian and Laird random effects model was used to analyze the treatment groups. The potential presence of publication bias was examined visually by inspecting funnel plots and statistically by using the Egger’s regression model [15].

Results

Literature Selection and Study Characteristics

Of the 345 articles found in our initial search, 803 were excluded by screening the titles and abstracts (Figure 1). The remaining 42 articles were potentially eligible trials that examined the effects of the calcimimetic agents. Of the 42 articles, 27 were further excluded due to the reasons indicated in Figure 1. Ultimately, 15 trials were included, all of which were performed between 2000 and 2011, enrolling a total of 3387 dialysis patients [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30]. None of the conference abstracts met the inclusion criteria and therefore were not included for analysis. Multiple publications were excluded from the count of included studies because they were secondary publications of previous reports; however, any relevant and unique results were extracted and included [26,29,30,31,32,33,34]. Table 1 shows the characteristics of the populations and interventions of all studies included in this meta-analysis. They compared a calcimimetic agent plus standard therapy with the placebo plus standard therapy or cinacalcet plus low-dose vitamin D sterols with flexible doses of vitamin D sterols. The treatment duration ranged from 1 to 52 weeks.

The quality of the 15 included trials were assessed using the three-question instrument proposed by Jadad et al. [11] (Table 1). All 15 trials included statements regarding randomization, including seven trials that described the detailed methods used for randomization [21,22,23,24,25,27,28]. Thus, all trials were scored as 1 or 2 based on the randomization criteria. 12 trials that reported adequate withdrawals and drop-outs were scored as 1, while the other 3 trials were scored as 0 [22,25,27]. Twelve trials that reported an appropriate binding method were scored as 1–2, while the other three trials were open-label and were scored as 0 [26,29,30].

Effects on Biochemical Outcomes

The iPTH value was significantly lower in the calcimimetics group than that in control therapy group (9 trials, 2480 patients; WMD, −294.36 pg/mL; 95% CI, −322.76 to −265.95, P<0.001; without significant heterogeneity, P=0.000, I2=44%, Figure 2) and a significantly greater proportion of patients in calcimimetics therapy showed a ≥30% decrease in mean iPTH vs. the baseline as compared with the control group (OR=10.75, 95% CI: 6.65–17.37, P<0.001). Similarly, serum calcium values (10 trials, 2663 patients; WMD, −0.81 mg/dL; 95% CI, −0.99 to −0.62, P<0.001; without heterogeneity, P=0.740, I2=0%, Figure 3), serum phosphorus (9 trials, 2631 patients; WMD, −0.29 mg/dL; 95% CI, −0.41 to −0.17, P<0.001; with no significant heterogeneity, P=0.850, I2=0%, Figure 4) and calcium-phosphorus product (8 trials, 2240 patients; WMD, −7.68 mg2/dL2; 95% CI, −8.93 to −6.43, P<0.001; with no significant heterogeneity of these trial results, P=0.470, I2=0%) were significantly lower in the calcimimetics group than that in control therapy group.
There was no significant difference in bone alkaline phosphatase between the two groups (3 trials, 284 patients; WMD, 1.79 U/L; 95% CI, −7.14 to 10.71, \( P = 0.690 \); without heterogeneity, \( P = 0.170, I^2 = 44\% \)). The osteocalcin (2 trials, 252 patients; WMD, −46.85 ng/ml; 95% CI, −80.51 to −13.18; \( P = 0.006 \); with significant heterogeneity, \( P = 0.130, I^2 = 55\% \)) and tartrate-resistant acid phosphatase levels (WMD, −1.33 ng/ml; 95% CI, −2.01 to −0.65; \( P = 0.001 \); with no significant heterogeneity, \( P = 0.390, I^2 = 0\% \)) were significantly lower in calcimimetics group than those in control therapy group.

Effects on Patient-level Outcomes

Six trials reported all-cause mortality (Table 2). Eight trials reported all adverse events including hypocalcemia, nausea, vomiting, diarrhea, dyspnea, upper respiratory tract infection, and headache. There was no significant difference in all-cause mortality and all adverse events between calcimimetics group and control therapy group (OR = 0.86, 95% CI: 0.46–1.60, \( P = 0.630 \); OR = 1.30, 95% CI: 0.78–2.18, \( P = 0.320 \), respectively). Compared with control therapy, a statistically significant increase for hypocalcemia was observed in calcimimetics group (OR = 2.46, 95% CI: 1.58–3.82, \( P < 0.001 \)). Calcimimetic therapy also led to more nausea (OR = 2.45, 95% CI: 1.29–4.66, \( P = 0.006 \)), vomiting (OR = 2.78, 95% CI: 2.14–3.62, \( P < 0.001 \)) and diarrhea (OR = 1.51, 95% CI: 1.04–2.20, \( P = 0.030 \)). Treatment with calcimimetic resulted in more upper respiratory tract infection, but not dyspnea or headache (OR = 1.97, 95% CI: 0.87–4.45, \( P = 0.100 \); OR = 1.62, 95% CI: 0.97–2.72, \( P = 0.070 \), respectively).

---

**Figure 1. Procedure used for the trial selection.** Abbreviation: RCT, randomized controlled trial. doi:10.1371/journal.pone.0048070.g001
The pooled ORs for all adverse events and nausea were performed using the random-effect model because of heterogeneities. There was no significant heterogeneity for other patient-level outcomes.

Sensitivity Analysis
Further analysis of the results using the fixed effect and random effect models showed the identical results, except all adverse events

Table 1. Characteristics of Trials of Calcimimetic Agents for SHPT in Dialysis Patients.

| Reference               | No. of Patients (treatment/control) | Dialysis vintage (treatment/control) | Interventions | Treatment Group (target iPTH) | Control | Duration | Jadad Score |
|-------------------------|------------------------------------|--------------------------------------|---------------|-------------------------------|---------|----------|-------------|
| Goodman et al, 2000     | 21 (16/5)                          | 6.76 ± 1.0 y/8.36 ± 1.7 y           | R-568, 100 mg/d | Placebo                       | 15d     | 3        |
| Goodman et al, 2002     | 52 (40/12)                         | ≥3 mo                                | AMG073, 5–100 mg/d | Placebo                       | 3d single dose, 8d multiple doses, follow up 15d after the begin | 3        |
| Quarles et al, 2003     | 71 (36/35)                         | 71.3 ± 54.3 mo/71.1 ± 66.2 mo       | AMG073, 25–100 mg/d (iPTH decrease ≥30%) | Placebo                       | 18w (Titration, 12w; maintenance, 6w) | 3        |
| Lindberg et al, 2003    | 78 (39/39)                         | 65.1 ± 55.9 mo                      | AMG073, 10–50 mg/d (iPTH decrease≥30%) | Placebo                       | 18w (Titration, 12w; maintenance, 6w) | 4        |
| Block et al, 2004       | 741 (371/370)                      | 72.6 ± 63 mo/72.6 ± 68 mo           | Cin, 30–180 mg/d (iPTH < 250 pg/mL) | Placebo                       | 26 w (Titration, 12w; maintenance, 14w) | 3        |
| Harris et al, 2004      | 23 (17/6)                          | HD                                   | Cin, 25 mg-300mg/d | Placebo                       | 1w of each dosing period | 3        |
| Lindberg et al, 2005    | 395 (294/101)                      | 56.4 ± 53.1 mo/63.6 ± 65.0 mo       | Cin, 30–180 mg/d (iPTH < 250 pg/mL) | Placebo                       | 26w (Titration, 16w; maintenance, 10w) | 4        |
| Martin et al, 2005      | 410 (205/205)                      | 67.5 ± 6 mo/62.5 ± 55 mo            | Cin, 30–180 mg/d (iPTH < 250 pg/mL) | Placebo                       | 26w     | 4        |
| Sterrett et al, 2007    | 210 (99/111)                       | ≥3 mo                                | Cin, 30–180 mg/d | Placebo                       | 52w     | 4        |
| Akiba et al, 2008       | 109 (79/30)                        | approximately 150 mo                | Cin, 12.3 mg/d, 25 mg/d, 50 mg/d | Placebo                       | Treatment, 3w; Follow-up, 2w | 5        |
| Fishbane et al, 2008    | 173 (87/86) (ACHEIVE)              | 46.3 ± 36.4 mo/46.8 ± 44.1 mo      | Cin (30–180 mg/d) plus low-dose active VitD (iPTH 150–300 pg/mL) | Vit D | 33w (Screening, 6w; Titration, 16w; Efficacy-assessment, 11w) | 2        |
| Fukagawa et al, 2008    | 144 (72/71)                        | 170.4 ± 93.7 mo/173.3 ± 76.0 mo    | Cin, 25–100 mg/d (iPTH < 250 pg/mL) | Placebo                       | Screening period, 4w; Treatment period, 14w | 4        |
| Malluche et al, 2008    | 48 (32/16)                         | ≥1 mo                                | Cin, 30–180 mg/d (iPTH < 200 pg/mL) | Placebo with Vit D and/or P binders | 52w (Titration, 24w; maintenance, 28w) | 4        |
| Messa et al, 2008       | 552 (368/184) (OPTIMA)            | 64.1 ± 72.1mo/69.4 ± 73.6mo        | Cin, 30–180 mg/d (iPTH < 200 pg/mL) | Conventional care | Dose-optimization, 16w; Efficacy-assessment, 7w | 2        |
| Raggi et al, 2011       | 360 (180/180) (ADVANCE)           | 37.5 mo (9.3, 105.0) Median/36.7 mo (10.0, 107.5) Median | Cin (30–180 mg/d) plus low-doseVitD active Vit D (iPTH < 300 pg/mL) | 52w (Titration, 20w; maintenance, 32w) | 2        |

Abbreviations: SHPT, secondary hyperparathyroidism; iPTH, intact PTH; HD, hemodialysis; Cin, Cinacalcet; Vit, Vitamin; d, day; w, week; mo, month; doi:10.1371/journal.pone.0048070.t001

Figure 2. Forest plot of iPTH of patients treated with calcimimetics and control therapy. Studies are identified by name of the first author and year of publication. Mean differences (MDs) are pooled using the fixed-effect model and shown on a scale of −500 to 500.
doi:10.1371/journal.pone.0048070.g002
which should be interpreted with caution (Table 2). Twelve of the 15 included studies compared calcimimetic agents with placebos; two trials compared cinacalcet plus low-dose active vitamin D with flexible dosing of active vitamin D [29,30]; and the remaining trial compared cinacalcet with conventional therapy [26]. The latter three trials were open-label and low quality (Jadad score lower than 3) [26,29,30]. The results were similar when the three trials were excluded.

**Publication Bias**

Publication bias was detected by using the Egger’s regression model, and the result showed that the publication bias was insignificant ($P = 0.724$). The funnel plots for publication bias (Figure 5) also showed symmetry. These results indicate that there was no publication bias.

**Discussion**

A comprehensive search was performed for randomized clinical trials that evaluated the efficacy and safety profile of calcimimetic agents, and finally 15 trials involving 3387 dialysis patient with SHPT met our inclusion criteria. Our meta-analysis showed that there was no significant difference in all-cause mortality and all adverse events between calcimimetics group and control therapy group. However, there was a statistically significant increase in the episodes of hypocalcemia, nausea, vomiting, diarrhea and upper respiratory tract infection in calcimimetics group as compared with control therapy group.

Our meta-analysis also showed that calcimimetic agents effectively ameliorated iPTH levels in patients with SHPT who were undergoing dialysis and reduced serum calcium and phosphorus disturbances associated with adverse clinical outcomes. The percentage of patients in whom there was a 30% decrease in serum iPTH by the end of the dosing was higher in cinacalcet group than that in the control group. Administration of vitamin D sterols and phosphate binders in four trials [18,21,22,24] was kept relatively constant to isolate the effect of cinacalcet. After excluding the four trials, we got the similar result with respect to iPTH (data not shown).

Tartrate-resistant acid phosphatase is an enzyme that is expressed in high amounts by bone resorbing osteoclasts [35], while osteocalcin is produced by osteoblasts and often used as a marker for bone formation [36]. Osteocalcin and tartrate-resistant acid phosphatase levels tended to be low in patients receiving calcimimetics, suggesting that cinacalcet may improve bone metabolism in dialysis patients. Bone alkaline phosphatase is
produced by osteoblasts and osteoblast precursors, and participates in bone mineralization. High serum levels of alkaline phosphatase result from osteoclastic hyperactivity. Bone alkaline phosphatase levels were correlated with histomorphometric parameters of bone formation and bone resorption [37]. As there was no statistically significant difference in bone alkaline phosphatase levels between cinacalcet group and the control group, whether bone alkaline phosphatase is useful for estimating bone changes during cinacalcet therapy remains to be elucidated.

Previous studies showed that calcimimetic agents could suppress parathyroid hyperplasia and ameliorate osteitis fibrosa in chronic renal insufficiency models [38,39]. In the included trials, only one trial [28] assessed the effect of cinacalcet on bone histology and showed that cinacalcet treatment reduced bone turnover and tissue fibrosis in SHPT patients receiving dialysis. Adynamic bone was also observed in three patients who received cinacalcet, and overexpression of iPTH (<100 pg/ml) was detected in two of them. It should be noted that PTH oversuppression may not be beneficial and could be associated with increased risk for low

### Table 2. Effect of calcimimetics and control therapy on patient-level outcomes (All-cause mortality, all adverse events, hypocalcemia, nausea, vomiting, diarrhea, dyspnea, upper respiratory tract infection and headache).

|                      | Fixed-effects Model | Random-effects Model | Heterogeneity |
|----------------------|---------------------|----------------------|---------------|
|                      | OR (95%CI)          | P value              | OR (95%CI)    | P value  | P value | I² (%) |
| All adverse events   | 1.43 (1.14, 1.80)   | 0.002                | 1.30 (0.78, 2.18) | 0.320    | <0.001  | 74%    |
| All-cause mortality  | 0.86 (0.46, 1.60)   | 0.630                | 0.86 (0.46, 1.60) | 0.630    | 0.980   | 0%     |
| Hypocalcemia         | 2.46 (1.58, 3.82)   | <0.001               | 2.45 (1.11, 5.41) | 0.030    | 0.190   | 32%    |
| Nausea               | 2.45 (1.29, 4.66)   | 0.006                | 2.53 (2.01, 3.18) | <0.001   | <0.001  | 79%    |
| Vomiting             | 2.78 (2.14, 3.62)   | <0.001               | 2.73 (2.07, 3.60) | <0.001   | <0.001  | 79%    |
| Diarrhea             | 1.51 (1.04, 2.20)   | 0.030                | 1.49 (1.01, 2.22) | 0.050    | 0.370   | 4%     |
| Dyspnea              | 1.97 (0.87, 4.45)   | 0.100                | 1.93 (0.85, 4.40) | 0.120    | 0.630   | 0%     |
| Upper respiratory    | 1.79 (1.20, 2.66)   | 0.004                | 1.79 (1.20, 2.67) | 0.004    | 0.480   | 0%     |
| tract infection      |                     |                      |               |          |         |        |
| Headache             | 1.62 (0.97, 2.72)   | 0.070                | 1.60 (0.95, 2.69) | 0.080    | 0.720   | 0%     |

**Abbreviations:** OR, Odds ratio; 95%CI, 95% confidence interval; doi:10.1371/journal.pone.0048070.t002

**Figure 5. Funnel graph for the assessment of potential publication bias in iPTH.** The funnel graph plots the MD against the SE of the MD. The dashed line indicates 95% confidence limits of the MD. The funnel plots show approximate symmetry. The result of the Egger’s test for publication bias was not significant (P=0.724).
doi:10.1371/journal.pone.0048070.g005
monitoring and the cinacalcet dosage should be adjusted during the reduced or discontinued. Hence, iPTH levels should be closely monitored and the cinacalcet dosage should be adjusted during the treatment.

Coronary artery calcification is a common and severe problem that is associated with ischemic cardiovascular disease and mortality in adult ESRD patients [40]. Compared with control treatment, there was no evidence that cinacalcet reduced all-cause mortality and cardiovascular mortality. The ADVANCE study [29] evaluated the effects of cinacalcet plus low-dose vitamin D on vascular calcification in hemodialysis patients and demonstrated that increases in calcification scores were less in the aorta, iliac and mitral valve in patients treated with cinacalcet plus low-dose vitamin D sterols, suggesting that cinacalcet treatment and low-dose vitamin D sterols may attenuate the progression of established cardiovascular calcification in patients receiving hemodialysis. More clinical evidence is needed to see whether cinacalcet is associated with a survival benefit in dialysis patients.

The most commonly reported adverse events are gastrointestinal adverse events and hypocalcemia. The mechanisms of gastrointestinal adverse events remain unclear, and further basic and clinical studies are needed. Hypocalcemia is considered to result from the loss of the effects of PTH on calcium reabsorption from the distal nephron or reduced bone resorption [41]. There were a small number of drop-outs caused by hypocalcemic events, although hypocalcemia could be managed by adjustment of the cinacalcet dose or increasing the dose of calcium and/or vitamin D sterols. The long-term effect of hypocalcemia remains uncertain.

The major limitation of this meta-analysis is that the number of published studies on calcimimetic agents in dialysis patients with SHPT is limited. The duration of most of these trials ranged from 1 to 52 weeks. Three of these trials were relatively small and lasted a relatively short time [17,18,19]. After excluding the three trials, we got the similar result (data not shown). Only two trials [21,26] included peritoneal patients, and therefore larger samples are required to examine the effect of cinacalcet in peritoneal patients. Nevertheless, the generalizability of all meta-analyses is limited by protocol heterogeneity and differences among study populations. In this study, the results of osteocalcin, all adverse events and nausea were considered heterogeneous. A random-effects analysis was used to account for potential differential effects across studies. In sensitivity analysis, we further analyzed the results by using both fixed effect and random effect models, and the results obtained were identical, except for all adverse events.

In conclusion, the results of this meta-analysis indicate the potential of calcimimetic agents as a treatment for dialysis patients with SHPT. Future studies are needed to assess the effects of cinacalcet on parathyroid hormone levels, vascular calcification, bone histomorphometry, or other hard clinical outcomes in larger samples with longer durations.

Supporting Information

Table S1 PRISMA flow diagram of this meta-analysis. (DOC)

Checklist S1 PRISMA Checklist of this meta-analysis. (DOC)

Author Contributions

Conceived and designed the experiments: QZ ML. Performed the experiments: QZ YG LN HL. Analyzed the data: QZ LY. Contributed reagents/materials/analysis tools: QZ ML YG LN CH JC.

References

1. Parfitt AM (1997) The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52: 3–9.
2. Goodman WG, Goldberg J, Kuizon BD, Yoon C, Gales B, et al. (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1470–1476.
3. Gonzalez EA, Martin KJ (1995) Renal osteodystrophy: pathogenesis and management. Nephrol Dial Transplant 10 Suppl 3: 13–21.
4. Bridgman AS, Harenbover DL, Norman AW, Coburn JW (1977) Actions of 1-alkyl hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on mineral metabolism in man. I. Effects on net absorption of phosphorus. Am J Clin Nutr 30(7): 1064–9.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl: S1–130.
6. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, et al. (1993) Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366: 575–580.
7. Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239–297.
8. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, et al. (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627–635.
9. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, et al. (2006) Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47: 715–726.
10. Higgins JPT, Green S, Cochrane Collaboration (2008) Cochrane handbook for systematic reviews of interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell. xxii, 616 p.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
12. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820–826.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
14. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408–412.
15. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
16. Block GA, Martin KJ, de Francisco Al, Turner SA, Avram MM, et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525.
17. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, et al. (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58: 436–445.
18. Goodman WG, Hasdik GA, Turner SA, Blaindell PW, Goodkin DA, et al. (2002) The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13: 1017–1024.
19. Harris RZ, Padhli D, Marbury TC, Noveck RJ, Salhi M, et al. (2004) Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 44: 1070–1076.
20. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, et al. (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248–254.
21. Lindberg JS, Calleton B, Wong G, Borah MF, Clark RV, et al. (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800–807.
22. Quares MD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, et al. (2005) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575–583.
23. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, et al. (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23: 329–335.
24. Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, et al. (2008) Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 12: 117–125.
25. Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, et al. (2005) First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 68: 1236–1243.

26. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, et al. (2008) The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3: 36–45.

27. Sterrett JR, Stroom J, Stummvoll HK, Bahner U, Disney A, et al. (2007) Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68: 10–17.

28. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, et al. (2008) An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69: 269–278.

29. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, et al. (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26: 1327–1339.

30. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, et al. (2008) Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHEVE study results. Clin J Am Soc Nephrol 3: 1718–1725.

31. Wilkie M, Pontoriero G, Macario F, Yaqoob M, Bouman K, et al. (2009) Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. Nephrol Clin Pract 112: e41–50.

32. Floege J, Raggi P, Block GA, Torres PU, Calky B, et al. (2010) Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in hemodialysis patients. Nephrol Dial Transplant 25: 1916–1923.

33. Shireman TI, Almeini A, Wetmore JB, Lu J, Pregenzer M, et al. (2010) Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 56: 1108–1116.

34. Wetmore JB, Liu S, Kebbell R, Menard R, Quares LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5: 110–116.

35. Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34: 285–290.

36. Ferreira A (1998) Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy: what do we have, what do we need? Nephrol Dial Transplant 13 Suppl 3: 29–32.

37. Urena P, Hruba A, Ferreira A, Ang KS, de Vernejoul MC (1996) Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7: 506–512.

38. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, et al. (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100: 2977–2983.

39. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, et al. (1998) NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53(2): 448–53.

40. Salgueira M, del Toro N, Moreno-Alba R, Jimenez E, Arete N, et al. (2003) Vascular calcification in the uraemic patient: a cardiovascular risk? Kidney Int Suppl: S119–121.

41. Bindels RJ (1993) Calcium handling by the mammalian kidney. J Exp Biol 184: 89–104.